Vesicular stomatitis virus matrix protein (VSVMP) inhibits the cell growth and tumor angiogenesis in oral squamous cell carcinoma

Oral Oncol. 2012 Feb;48(2):110-6. doi: 10.1016/j.oraloncology.2011.09.007. Epub 2011 Oct 26.

Abstract

The purpose of this study was to investigate the anticancer property of vesicular stomatitis virus matrix protein (VSVMP) in oral squamous cell carcinoma (OSCC) via in vitro and in vivo approaches. In this study, we found that OSCC cells treated with VSVMP showed retarded cell growth in vitro. The percentage of apoptotic cells in VSVMP group was much higher than that of the control groups. Moreover, our in vivo experiments showed that the growth of tumor xenografts was significantly suppressed by VSVMP treatment without any obvious side effects. Further studies revealed that the suppression of tumor growth may be caused by the synergistic effect of VSVMP related cell apoptosis enhancing and tumor angiogenesis suppression, and the latter is most likely correlated with the suppression of VEGF pathway. This study indicated that VSVMP treatment can effectively inhibited the cell growth and tumor angiogenesis in OSCC without obvious adverse effects. Therefore, VSVMP might be a potential and efficient strategy for OSCC treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects*
  • Biological Assay
  • Blotting, Western
  • Carcinoma, Squamous Cell / blood supply
  • Carcinoma, Squamous Cell / metabolism*
  • Female
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Mouth Neoplasms / blood supply
  • Mouth Neoplasms / metabolism*
  • Neovascularization, Pathologic / metabolism*
  • Viral Matrix Proteins / pharmacology*

Substances

  • M protein, Vesicular stomatitis virus
  • Viral Matrix Proteins